A detailed history of China Universal Asset Management Co., Ltd. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 31,903 shares of ACAD stock, worth $544,584. This represents 0.05% of its overall portfolio holdings.

Number of Shares
31,903
Previous 19,410 64.36%
Holding current value
$544,584
Previous $315,000 55.56%
% of portfolio
0.05%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$15.14 - $19.14 $189,144 - $239,116
12,493 Added 64.36%
31,903 $490,000
Q2 2024

Jul 19, 2024

SELL
$14.62 - $18.42 $179,007 - $225,534
-12,244 Reduced 38.68%
19,410 $315,000
Q1 2024

Apr 29, 2024

BUY
$17.79 - $30.86 $225,381 - $390,965
12,669 Added 66.73%
31,654 $585,000
Q4 2023

May 21, 2024

SELL
$20.78 - $31.77 $263,261 - $402,494
-12,669 Reduced 40.02%
18,985 $594,000
Q4 2023

Jan 23, 2024

BUY
$20.78 - $31.77 $307,190 - $469,655
14,783 Added 351.81%
18,985 $594,000
Q3 2023

May 21, 2024

BUY
$20.84 - $33.47 $43,138 - $69,282
2,070 Added 97.09%
4,202 $87,000
Q3 2023

Oct 30, 2023

BUY
$20.84 - $33.47 $43,138 - $69,282
2,070 Added 97.09%
4,202 $88,000
Q2 2023

May 21, 2024

SELL
$17.8 - $25.65 $1,174 - $1,692
-66 Reduced 3.0%
2,132 $51,000
Q2 2023

Jul 27, 2023

SELL
$17.8 - $25.65 $1,174 - $1,692
-66 Reduced 3.0%
2,132 $51,000
Q1 2023

May 21, 2024

BUY
$16.32 - $20.92 $9,024 - $11,568
553 Added 33.62%
2,198 $41,000
Q1 2023

Apr 27, 2023

BUY
$16.32 - $20.92 $9,024 - $11,568
553 Added 33.62%
2,198 $41,000
Q4 2022

May 21, 2024

SELL
$14.2 - $18.63 $426,127 - $559,067
-30,009 Reduced 94.8%
1,645 $26,000
Q4 2022

Jan 31, 2023

BUY
$14.2 - $18.63 $1,846 - $2,421
130 Added 8.58%
1,645 $26,000
Q3 2022

Oct 21, 2022

BUY
$14.11 - $18.27 $21,376 - $27,679
1,515 New
1,515 $25,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.